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Resveratrol is a polyphenol that is found in plants. it is synthesized in 
response to pathogenic stresses and fungal disease and forms part of a 
defence mechanism against infection.1 Red grapes, mulberries, and peanuts 
are particularly rich sources.2 a high concentration is found in red wine.
interest in therapeutic effects of resveratrol began with the French paradox 
describing a lower incidence of cardiovascular events among French 
populations despite a high intake of dietary fat.3 clinical studies have shown 
that resveratrol is a potent cardioprotective,4 chemotherapeutic,5 and 
neuroprotective6 agent and displays anti-aging properties.7 These effects are 
most likely attributable to potent anti-inflammatory and anti-oxidant properties.
age-related macular degeneration (aMd) is the leading cause of visual loss 
in those over the age of 50 years in the developed world.8–11 in the uS, the 
number of people affected by this condition is expected to increase from 
1.75 million to almost three million by 2020.11 The condition is characterized 
in part by an uncontrolled level of oxidation, which damages cell membranes 
and triggers inflammation. Resveratrol may have the potential to impact on 
the risk for onset or progression of this condition. developed world diets 
contain a very low concentration of resveratrol12 and increasingly it is being 
included in nutritional supplementation formulations. 
This review explores the scientific evidence documenting the properties 
of resveratrol relevant to aMd and its potential use in ocular nutritional 
supplements. The evidence presented here is from published literature 
located through systematic searches of PubMed and Web of Knowledge.
Methods
literature searches of PubMed and Web of Knowledge were undertaken. 
all searches performed were topic searches and Boolean operators 
were used to ensure that the results remain focused. an initial search 
performed on Web of Knowledge included the search criteria of 
resveratrol or polyphenol or phytoalexin or stilbenoid and eye or retina 
or ocular or vision or sight. other searches used the criteria resveratrol 
and anti-inflammatory, resveratrol and antioxidant, resveratrol and retina, 
resveratrol and age-related macul* and were performed on Web of 
Knowledge and PubMed. Both databases were set to automatically filter 
out any search results dated prior to 1950.
The relevancy of the remaining research results was checked by evaluation 
of the title against the proposed line of enquiry addressed in this review, 
namely the retinal effects of the resveratrol. if the title proved to be 
ambiguous, a decision was made by the authors based on the abstract 
as to whether the result was relevant. By performing the research in this 
way, it was hoped that the results identified would be specific to the eye. 
however, many experiments had been performed in vitro using cultured 
retinal or trabecular cells. These studies were included. 
To meet inclusion criteria, experimental work had to have a sound method 
with clear aims, stringent protocols, and a sufficiently substantial analysis 
together with details of numbers of subjects and appropriate statistical 
analysis if conducted. Significant variation was evident among the 
protocol deployed and the analytical techniques used even in literature 
pertaining to a similar topic. 
Bioavailability
in common with other polyphenols, resveratrol has an extremely 
limited bioavailability. although absorption is rapid13 and the extent of 
absorption is at least 70  % in humans,14 studies performed on rats15 
have shown that resveratrol undergoes rapid metabolism in the gut prior 
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to entering the systemic circulation. the presence of food significantly 
delays the absorption of resveratrol but does not alter the extent of it.16 
the reduction in the concentration of resveratrol entering the systemic 
circulation is compounded further by recirculation between the small 
intestine and the liver. metabolism occurs so rapidly that a conjugate of 
resveratrol was detected by high-performance liquid chromatography 
less than 10 minutes following intravenous infusion to human subjects. 
plasma was already devoid of resveratrol in two subjects at just 30 
minutes following the onset of infusion.17 the plasma concentration 
reached, although high (approximately 25  ng/ml), was far below the 
amount shown to elicit an effect in vitro (>1,000  ng/ml).7 however, 
resveratrol is a lipophilic compound that can be bound to the cellular 
fraction in blood. it is possible that its level in blood and in tissues is 
underestimated.18 Urinary excretion appears to be the main mode of 
disposal in humans.17
Safety
Studies conducted on humans to date have shown that resveratrol is safe 
and tolerated well. the only reported adverse effect in six human subjects 
who received 200 mg of resveratrol twice daily was incipient diarrhea but 
no clinically significant changes occurred in hematology or biochemistry.19 
in 40 human subjects receiving between 25 mg to 150 mg of resveratrol 
six times daily,20 five subjects reported headaches. Other reported 
adverse effects included drowsiness, dizziness, urinary tract infections, 
epididymitis, dyspepsia, and nasopharyngitis, but these were all reported 
only in individual subjects. isolated incidences of nasopharyngitis have 
been reported in two studies.16,20 Overall, adverse effects have been 
minor and resveratrol appears to have a good safety profile.
Inflammation and Age-related  
Macular Degeneration
there is an overwhelming body of evidence implicating inflammation 
in the pathogenesis of amD. a review21 described an altered balance of 
autoimmunity, chronic inflammation, and dysregulated parainflammation 
as triggers. the Blue mountains Eye Study22 found that the white blood 
cell count correlated positively with pigmentary abnormalities, drusen, 
and the incidence of early amD. another investigation23 revealed that the 
retinas of rats with experimentally induced choroidal neovascularization 
(cNV) contained a greater amount of lymphocyte-producing cells around 
the retinal vasculature compared with retinas without cNV. it is plausible 
that increased vascular permeability during amD permits the influx of 
macrophages to the retina.
there is unequivocal evidence for involvement of the complement system. 
Drusen have been found to contain components of the complement 
cascade and other immunoreactive material.24 hard and small drusen from 
eyes of postmortem amD patients were found to contain complements 
known to promote vascular endothelial growth factor (VEGF) secretion in 
human retinal pigment epithelial (RpE) cells.25 VEGF is pro-angiogenic. a 
dysregulated complement system that results in angiogenesis could be 
a contributor to the macrophage influx. activated complement has also 
been found at the outer edge of human basal laminar deposits and VEGF 
has been detected at the basal surface of the RpE.26 Further evidence for 
involvement of the complement cascade comes from studies that have 
shown that polymorphisms in complement factor h, an anti-inflammatory 
substance, predispose to amD.27,28 
Anti-inflammatory Properties of Resveratrol
there is good evidence substantiating the use of resveratrol as an anti-
inflammatory agent. Of particular relevance is the effect resveratrol has 
on the adhesion of inflammatory molecules to the retinal vasculature. 
administration of resveratrol to male mice with induced uveitis reduced 
the total number of leukocytes adhering to the retinal vasculature.29 
the same researchers found that resveratrol reduced the expression 
of two chemotactic adhesion molecules: in the retina and the RpE/
choroid again in the mouse model. Under conditions of hyperglycemia 
vascular permeability increases as does the secretion of VEGF. this has 
been shown to be inhibited by resveratrol (1.25 µm).30 Resveratrol may be 
useful in the treatment of hyperglycemia-induced inflammation.
Resveratrol is cytotoxic to macrophages and impairs their ability to 
proliferate31 and reduces the expression of inflammatory mediators.32 the 
benzene rings appear to play an essential role in the anti-inflammatory 
properties of resveratrol.33 Resveratrol has been shown to reduce induced 
edema by 38.9 % in the mouse model an effect similar to that of ibuprofen 
(also contains a single benzene ring), which reduced edema by 42.2 %.
Anti-oxidant Effects of Resveratrol
the retina is exposed to a significant degree of oxidative stress due to the 
presence of susceptible membranous fatty acids (e.g. docosahexenoic acid 
[Dha]), the influx of light acts as a catalyst for oxidative reactions and a 
naturally high oxygen tension.34 Evidence suggests that oxidative damage 
to cells reflects an impaired ability of the cells to ameliorate oxidative stress.
Yildirim et al. found higher serum levels of markers for lipid and protein 
oxidation in subjects with amD and cNV and compared with unaffected 
controls.35 participants with amD had a significantly lower level of the anti-
oxidant superoxide dismutase. most of the oxidative damage takes place in 
the cell membrane and the damaged membrane triggers an inflammatory 
cascade. products of the oxidation of Dha were shown to cause lesions in 
the RpE, activate the complement pathway, and cause a swelling of Bruch’s 
membrane.36 the likely trigger appears to be disordered phospholipid.37 
these findings demonstrate the importance of reducing the amount of 
oxidation that occurs in the retina of amD patients. Suppression of the 
complement cascade through the selective targeting of oxidation and 
inflammation would therefore seem to be important in any therapy for amD. 
Resveratrol has displayed potent antioxidant properties, although many 
of the investigations have been conducted in vitro. however, the limited 
results from in vivo experiments have demonstrated that resveratrol is a 
potent scavenger of free radical species. Resveratrol is also very effective 
at scavenging superoxide38 and hydroxyl radicals.2
Resveratrol protects against hydrogen peroxide toxicity and apoptosis 
of human lens epithelial cells in a dose-dependent manner39 and was 
reported to reduce reactive oxygen species (ROS) levels in porcine 
trabecular meshwork.40
Angiogenesis in Age-related  
Macular Degeneration
cNV appears to represent changes in Bruch’s membrane including 
thinning in some places, permitting breach by new blood vessels. it is 
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particularly common after photodynamic therapy,41 an indication that 
cNV may be induced by an overexposure to light. the occurrence of 
cNV denotes the influence of pro-angiogenic mediators dominating anti-
angiogenic mediators. in support of this, macular levels of endogenous 
inhibitors of angiogenesis, such as endostatin, thrombospondin-1, 
and pigment epithelium-derived factor, are significantly reduced in 
amD patients compared with controls.42 During this pathogenic state, 
normally observed during the late form of amD, new blood vessels 
radiate outward from the choroid, breaching Bruch’s membrane, and 
proliferating into the RpE or subretinal space.43 angiogenesis is mediated 
through the alternative inflammation pathway. Factor h inhibits the 
alternative inflammatory pathway44 and a recombinant form of factor h 
(cR2-fh) reduces the severity of laser-induced cNV in mice.45 the anti-
inflammatory and anti-oxidative properties of resveratrol may help to 
reduce the incidence of cNV.
Anti-proliferative/Anti-angiogenic  
Effects of Resveratrol
Resveratrol has demonstrated particularly good anti-proliferative 
properties. King et al. found that resveratrol reduced the proliferation of 
RpE cells in a dose-dependent manner.46 cao et al. found that resveratrol 
reduced the migration of human umbilical vein endothelial cells47 
while hua et al. revealed that resveratrol suppressed the migration of 
human renal microvascular endothelial cells.48
as resveratrol is able to annul cell migration and the proliferation of 
endothelial cells in particular, it is unsurprising that experimental work 
has shown that resveratrol reduces angiogenesis. Resveratrol reduced 
the number of subretinal neovascular lesions in mice and angiogenesis in 
mice with laser-induced cNV.49 
Nitric oxide (NOS) is a pro-angiogenic growth factor.50 Resveratrol has 
been shown to inhibit production of NOS in mouse macrophages51 
and the secretion of VEGF that occurs in response to the presence 
of oxysterols. these are products of cholesterol oxidation liberated 
during degradation of membranes of cells in the RpE. Rats bred in 
hypoxic conditions have neovascularization, fibrovascular growth, and 
extravasation of blood52 partly due to the formation of NOS. this was 
reduced by resveratrol. 
Conclusion
Resveratrol has poor bioavailability, a good safety profile, and is thought 
to act on inflammatory, oxidative, and pro-angiogenic mediators that 
are involved in the pathogenesis of amD. Resveratrol has the potential 
to play a role in the treatment of a range of retinal conditions and in 
particular amD. Further research using the human model and double-
masked placebo-controlled experimental protocols would be of value in 
order to determine its efficacy and full potential as a component of ocular 
nutritional supplements. n
1.  tosun i, inkaya aN, Resveratrol as a health and disease benefit 
agent, Food Rev Intern, 2010;26:85–101.
2.   leonard SS, Xia c, Jiang Bh, et al., Resveratrol scavenges 
reactive oxygen species and effects radical-induced cellular 
responses, Biochem Biophys Res Commun, 2003;309:1017–26.
3.   lippi G, Franchini m, Favaloro EJ, et al., moderate red wine 
consumption and cardiovascular disease risk: Beyond the 
“French paradox”, Semin Thromb Hemost, 2010;36:59–70.
4.   Wu Jm, hsieh tc, Resveratrol: a cardioprotective substance,  
Ann N Y Acad Sci, 2011;1215:16–21.
5.   Gusman J, malonne h, atassi G, a reappraisal of the potential 
chemopreventive and chemotherapeutic properties of 
resveratrol, Carcinogenesis, 2001;22:1111–17.
6.   Richard t, pawlus aD, iglesias ml, et al., Neuroprotective 
properties of resveratrol and derivatives, Ann N Y Acad Sci, 
2011;1215:103–8.
7.   alarcon de la lastra c, Villegas i, Resveratrol as an anti-
inflammatory and anti-aging agent: mechanisms and clinical 
implications, Mol Nutr Food Res, 2005;49:405–30.
8.   attebo K, mitchell p, Smith W, Visual acuity and the causes 
of visual loss in australia. the Blue mountains eye study, 
Ophthalmol, 1996;103:357–64.
9.   mitchell p, Smith W, attebo K, et al., prevalence of age-related 
maculopathy in australia – the Blue mountains eye study, 
Ophthalmol, 1995;102:1450–60.
10.   Klein R, Wang Q, Klein B, the relationship of age-related 
maculopathy, cataract, and glaucoma to visual acuity, Invest 
Ophthalmol Vis Sci, 1995;36:182–91.
11.   Friedman D, O’colmain B, tomany S, et al., the Eye Diseases 
prevalence Research Group, prevalence of age-related 
macular degeneration in the United States, Arch Ophthalmol, 
2004;122:564–72.
12.   Espin Jc, Garcia-conesa mt, tomas-Barberan Fa, Nutraceuticals: 
Facts and fiction, Phytochem, 2007;68:2986–3008.
13.   azorin-Ortuno m, Yanez-Gascon mJ, Vallejo F, et al., metabolites 
and tissue distribution of resveratrol in the pig, Mol Nutr Food 
Res, 2011;55:1154–68.
14.   Walle t, Bioavailability of resveratrol, Resveratrol and health,  
Ann N Y Acad Sci, 2011;1215:9–15.
15.   Kuhlne G, Spencer J, chowrimootoo G, et al., Resveratrol is 
absorbed in the small intestine as resveratrol glucuronide, 
Biochem Biophys Res Commun, 2000;272:212–17.
16.   Vaz-Da-Silva m, loureiro ai, Falcao a, et al., Effect of food on the 
pharmacokinetic profile of trans-resveratrol, Int J Clin Pharmacol 
Ther, 2008;46:564–70.
17.   Walle t, hsieh F, Delegge mh, et al., high absorption but very 
low bioavailability of oral resveratrol in humans, Drug Metab 
Dispos, 2004;32:1377–82.
18.   Soleas G, Yan J, Goldberg D, measurement of trans-resveratrol, 
(1)-catechin, and quercetin in rat and human blood and urine 
by gas chromatography with mass selective detection, Methods 
Enzymol, 2001;335:130–45.
19.   la porte c, Voduc N, Zhang GJ, et al., Steady-state 
pharmacokinetics and tolerability of trans-resveratrol 2000 mg 
twice daily with food, quercetin and alcohol (ethanol) in healthy 
human subjects, Clin Pharmacokinet, 2010;49:449–54.
20.   almeida l, Vaz-da-Silva m, Falcao a, et al., pharmacokinetic and 
safety profile of trans-resveratrol in a rising multiple-dose study 
in healthy volunteers, Mol Nutr Food Res, 2009;53:S7–S15.
21.  Buschini E, piras a, Nuzzi R, et al., age related macular 
degeneration and drusen: Neuroinflammation in the retina,  
Prog Neurobiol, 2011;95:14–25.
22.   Shankar a, mitchell p, Rochtchina E, et al., association between 
circulating white blood cell count and long-term incidence of 
age-related macular degeneration: the Blue mountains eye 
study, Am J Epidemiol, 2007;165:375–82.
23.   caicedo a, Espinosa-heidmann DG, pina Y, et al., Blood-derived 
macrophages infiltrate the retina and activate muller glial cells 
under experimental choroidal neovascularization, Exp Eye Res, 
2005;81:38–47.
24.   Johnson lV, leitner Wp, Staples mK, et al., complement 
activation and inflammatory processes in drusen formation and 
age related macular degeneration, Exp Eye Res, 2001;73:887–96.
25.   Nozaki m, Raisler BJ, Sakurai E, et al., Drusen complement 
components c3a and c5a promote choroidal neovascularization, 
Proc Natl Acad Sci U S A, 2006;103:2328–33.
26.   lommatzsch a, hermans p, muller KD, et al., are low 
inflammatory reactions involved in exudative age-related 
macular degeneration? morphological and immunhistochemical 
analysis of amd associated with basal deposits, Graefes Arch 
Clin Exp Ophthalmol, 2008;246:803–10.
27.   Despriet DD, Klaver cc, Witteman Jc, et al., complement factor 
h polymorphism, complement activators, and risk of age-related 
macular degeneration, JAMA, 2006;296:301–9.
28.   Narayanan R, Butani V, Boyer DS, et al., complement factor h 
polymorphism in age-related macular degeneration, Am Acad 
Ophthalmol, 2006;114:1327–31.
29.   Kubota S, Kurihara t, mochimaru h, et al., prevention of ocular 
inflammation in endotoxin-induced uveitis with resveratrol 
by inhibiting oxidative damage and nuclear factor-kappa b 
activation, Investigative Ophthalmol Vis Sci, 2009;50:3512–19.
30.   losso JN, truax RE, Richard G, trans-resveratrol inhibits 
hyperglycemia-induced inflammation and connexin 
downregulation in retinal pigment epithelial cells, J Agri Food 
Chem, 2010;58:8246–52.
31.   Billack B, Radkar V, adiabouah c, In vitro evaluation of the 
cytotoxic and anti-proliferative properties of resveratrol and 
several of its analogs, Cell Mol Biol Lett, 2008;13:553–69.
32.   Kim mh, Yoo DS, lee SY, et al., the trif/tbk1/irf-3 activation 
pathway is the primary inhibitory target of resveratrol, 
contributing to its broad-spectrum anti-inflammatory effects, 
Pharmazie, 2011;66:293–300.
33.   chen G, Shan W, Wu Yl, et al., Synthesis and anti-inflammatory 
activity of resveratrol analogs, Chem Pharm Bull, 2005;53:1587–
90.
34.   Beatty S, Koh hh, henson D, et al., the role of oxidative stress 
in the pathogenesis of age-related macular degeneration, Surv 
Ophthalmol, 2000;45:115–34.
35.   Yildirim Z, Ucgun Ni, Yildirim F, the role of oxidative stress 
and antioxidants in the pathogenesis of age-related macular 
degeneration, Clinics (Sao Paulo), 2011;66:743–6.
36.   hollyfield JG, perez Vl, Salomon RG, a hapten generated from 
an oxidation fragment of docosahexaenoic acid is sufficient 
to initiate age-related macular degeneration, Mol Neurobiol, 
2010;41:290–98.
37.   chen R, Yang l, mcintyre tm, cytotoxic phospholipid oxidation 
products. cell death from mitochondrial damage and the 
intrinsic caspase cascade, J Biol Chem, 2007;282:24842–50.
38.   Gulcin i, antioxidant properties of resveratrol: a structure-
activity insight, Innov Food Sci Emerging Technol, 2010;11:210–
18.
39.   Zheng Y, liu Yh, Ge JY, et al., Resveratrol protects human 
lens epithelial cells against h(2)o(2)- induced oxidative stress 
by increasing catalase, sod-1, and ho-1 expression, Mol Vis, 
2010;16:1467–74.
40.   luna c, li GR, liton pB, et al., Resveratrol prevents the expression 
of glaucoma markers induced by chronic oxidative stress in 
trabecular meshwork cells, Food Chem Toxicol, 2009;47:198–204.
41.   potter mJ, Szabo Sm, Recurrence of choroidal 
neovascularisation after photodynamic therapy in patients 
with age-related macular degeneration, Br J Ophthalmol, 
2007;91:753–6.
42.   Bhutto ia, Uno K, merges c, et al., Reduction of endogenous 
angiogenesis inhibitors in bruch’s membrane of the submacular 
region in eyes with age-related macular degeneration, Arch 
Ophthalmol, 2008;126:670–78.
43.   marneros aG, She h, Zambarakji h, et al., Endogenous 
endostatin inhibits choroidal neovascularization, FASEB J, 
2007;21:3809–18.
44.   Rohrer B, long Q, coughlin B, et al., a targeted inhibitor of the 
aternative complement pathway reduces angiogenesis in a 
mouse model of age-related macular degeneration, Invest 
Ophthalmol Vis Sci, 2009;50:3056–64.
45.   Rohrer B, long Q, coughlin B, et al., a targeted inhibitor of 
the complement alternative pathway reduces RpE injury and 
angiogenesis in models of age-related macular degeneration, 
Adv Exp Med Biol, 2010;703:137–49.
46.   King RE, Kent KD, Bomser Ja, Resveratrol reduces oxidation 
and proliferation of human retinal pigment epithelial cells via 
extracellular signal-regulated kinase inhibition, Chemico-Biolog 
Interact, 2005;151:143–9.
47.   cao l, liu h, lam DS-c, et al., In vitro screening for angiostatic 
potential of herbal chemicals, Invest Ophthalmol Vis Sci, 
2010;51:6658–64.
48.   hua J, Guerin Ki, chen J, et al., Resveratrol inhibits pathologic 
retinal neovascularization in vldlr(-/-) mice, Invest Ophthalmol 
Vis Sci, 2011;52:2809–16.
49.   Khan aa, Dace DS, Ryazanov aG, et al., Resveratrol regulates 
pathologic angiogenesis by a eukaryotic elongation factor-2 
kinase-regulated pathway, Am J Pathol, 2010;177:481–92.
50.   Zhang R, Wang l, Zhang l, et al., Nitric oxide enhances 
angiogenesis via the synthesis of vascular endothelial  
growth factor and cgmp after stroke in the rat, Circ Res, 
2003;92:308–13.
51.   chung EY, Kim Bh, hong J-t, et al., Resveratrol down-
regulates interferon-gamma-inducible inflammatory genes 
in macrophages: molecular mechanism via decreased stat-1 
activation, J Nutr Biochem, 2011;22:902–9.
52.   Kim Wt, Suh ES, Retinal protective effects of resveratrol via 
modulation of nitric oxide synthase on oxygen-induced 
retinopathy, Korean J Ophthalmol, 2010;24:108–18.
